Note: This document contains side effect information about methamphetamine. Some dosage forms listed on this page may not apply to the brand name Desoxyn.
Applies to methamphetamine: oral tablets.
Warning
Special Alerts:
A standardized concentration for this drug has been established through Standardize 4 Safety (S4S), a national patient safety initiative to reduce medication errors, especially during transitions of care. The drug is included in a standard concentration list which may apply to an IV or oral compounded liquid formulation. For additional information, see the ASHP website [Web].
FDA drug safety communication (5/11/2023):
To address continuing concerns of misuse, abuse, addiction, and overdose of prescription stimulants, FDA is requiring updates to the Boxed Warning and other information to ensure the prescribing information is consistent across the entire class of these drugs.
The current prescribing information in some prescription stimulants does not provide up to date warnings about the harms of misuse and abuse, particularly when these drugs are shared with individuals for whom they are not prescribed. An FDA review found that most individuals who misuse prescription stimulants obtain their drugs from family members or peers, and that such sharing of prescription stimulants was a major contributor to nonmedical use and addiction.
Updates will include information that patients should never share their prescription stimulants with anyone, and the Boxed Warning information will describe the risks of misuse, abuse, addiction, and overdose consistently across all medicines in the class. The Boxed Warning will also advise healthcare professionals to monitor patients closely for signs and symptoms of misuse, abuse, and addiction.
Side effects include:
Elevation of BP, tachycardia, palpitations, dizziness, dysphoria, overstimulation, insomnia, tremor, restlessness, headache, diarrhea, constipation, dry mouth, unpleasant taste, urticaria, impotence, changes in libido.
For Healthcare Professionals
Applies to methamphetamine: oral tablet, oral tablet extended release.
Cardiovascular
Frequency not reported: Elevated blood pressure, tachycardia, palpitation, fatal cardiorespiratory arrest
Postmarketing reports: Peripheral vasculopathy[Ref]
Musculoskeletal
Frequency not reported: Rhabdomyolysis, growth suppression[Ref]
Psychiatric
Rare (less than 0.1%): Psychotic episodes
Frequency not reported: Dysphoria, euphoria, insomnia, restlessness[Ref]
Nervous system
Frequency not reported: Dizziness, overstimulation, tremor, headache, exacerbation of motor/phonic tics and Tourette's syndrome[Ref]
Gastrointestinal
Frequency not reported: Diarrhea, constipation, dry mouth, unpleasant taste, other GI disturbances[Ref]
Endocrine
Frequency not reported: Impotence, libido changes, frequent or prolonged erections[Ref]
Hypersensitivity
Frequency not reported: Urticaria[Ref]
